ACT’s hESC-derived RPE cells receive EMA positive opinion for Orphan Medication Designation for Stargardt’s disease Advanced Cellular Technology, Inc. This opinion will today end up being forwarded by the EMA to the European Commission for his or her adoption, that ought to follow in arriving weeks . ‘We are very pleased to receive this positive opinion for Orphan Drug Designation from the EMA for our hESC-derived RPE cells for the treating Stargardt’s disease,’ stated Gary Rabin, ACT’s interim chairman and CEO. ‘There happens to be no accepted treatment for Stargardt’s disease, and we are working diligently to move this European trial ahead as quickly as possible. The scientists, employed in and in collaboration with the laboratory of Whitehead Member Susan Lindquist, established these previously unknown links in an unexpected way.